Avadel Pharmaceuticals — Investor Presentation (January 2017)
26 slides from Avadel Pharmaceuticals's investor presentation, Jan 11, 2017
Slide 1: Avadel Pharmaceuticals plc January 2017 Corporate Presentation
Avadel Pharmaceuticals plc January 2017 Corporate Presentation
Slide 2: Safe Harbor
2January 2017 Safe Harbor This presentation may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "assume," "believe," "expe
Slide 3: Investment Highlights
3January 2017 Investment Highlights Phase III Trial Growing Product Portfolio 2017 Outlook − 2016 revenues expected near $143 million − $149.7 million cash & marketable securities at 9/30/16 − Cash flow positive − No bank debt − Phase III trial FT218 − Current market size > $1 billion − Data expecte
Slide 4: Corporate Transformation
4January 2017 Corporate Transformation − Established in 1990 to provide life cycle solutions to large pharma using its polymer-based drug delivery technology − Coreg CR® using Micropump® received FDA approval (GSK partnered product) − Acquired Éclat Pharmaceuticals and transitions to specialty pharm
Slide 5: Management Team
5January 2017 Management Team Michael Anderson Chief Executive Officer • Appointed CEO in 2012 • Former CEO of Éclat Pharmaceuticals • Former President & CEO of generics business at KV Pharmaceutical Company • Former President & CEO of Ther-Rx Michael Kanan SVP, Chief Financial Officer • Appointed i
Slide 6: 2016 Performance Highlights
6January 2017 Performance Highlights Generated total revenue at the top end of guidance: $133 - $143 million Completed cross-border merger from France to Ireland Launched Akovaz™ (approved 4/29/16) Integrated pediatric products (acquired 2/8/16) Commenced dosing for REST-ON Phase III trial
Slide 7: Pipeline
7January 2017 Pipeline Completed feasibility and PK studies for both Medusa™ exenatide and Trigger Lock™ hydromorphone, and actively seeking to out license or divest these platforms* (AV001) * Please see our appendix for more details on these technologies OTC
Slide 8: Micropump Overview
8January 2017 Micropump® Overview Micropump® Granules: - Drug granulate or layered neutral core - Polymer coating - Consists of multiple-dose system containing from 5,000 – 50,000 micro particles Coating: - Diffusion control - pH independent/dependent - Film integrity preserved -- during GI track tr
Slide 9: LiquiTime Overview
9January 2017 LiquiTime® Overview • Intended for development of modified/controlled release liquid formulations for patients having issues swallowing tablets/capsules • Not limited to working solely with ionic drugs as with resin- complex based technologies • Easy-to-swallow, good mouthfeel, taste-m
Slide 10: Narcolepsy Overview
10January 2017 Narcolepsy Overview A sleep disorder, involving irregular patterns in Rapid Eye Movement (REM) sleep and significant disruptions of the normal sleep/wake cycle - Only 25% of people with narcolepsy have been diagnosed and are receiving treatment* - Sodium oxybate (Xyrem®) dosed 2x / ni
Slide 11: FT218: Potential for Improved Treatment
11January 2017 FT218: Potential for Improved Treatment FT218: Once-nightly formulation of sodium oxybate utilizing Avadel’s proprietary extended-release Micropump® micro/nano particle technology for oral suspension Studied in 40 healthy volunteers: Comparable AUC as Xyrem® on dose- for-dose basis
Slide 12: REST-ON Phase III Clinical Trial
12January 2017 Double-Blind, Randomized, Placebo-Controlled, Study to Assess Safety and Efficacy of Once Nightly Sodium Oxybate (FT218) for the Treatment of Excessive Daytime Sleepiness (EDS) and Cataplexy in Patients with Narcolepsy REST-ON Phase III Clinical Trial
Slide 13: REST-ON Phase III Trial
13January 2017 REST-ON Phase III Trial • 264 Patients, ages 16 + • 50 – 60 Clinical sites across US, Canada, Western Europe • Patients must be sodium oxybate naive • Efficacy measured by Maintenance of Wakefulness Test (MWT) and Clinical Global Impression (CGI) rating of sleepiness • Efficacy assess
Slide 14: Current Product Portfolio
14January 2017 Current Product Portfolio Hospital Products Pediatric Products
Slide 15: Hospital Products
15January 2017 Hospital Products Akovaz™ (ephedrine sulfate injection) • Market volume ~ 7 million vials / year Bloxiverz® (neostigmine methylsulfate injection) • Market volume ~ 4 million vials / year Vazculep® (phenylephrine hydrochloride) • Market volume 1mL vial – 5.7 million 5mL vial – 1.2 M 10
Slide 16: Pediatrics
16January 2017 Pediatrics • Acquired 3 commercial stage pediatric-focused products (February 2016) • Flexichamber® launch planned for the end of 1Q 2017 • Actively seeking to acquire additional products to fold into sales force For full prescribing information on these products, please see the appen
Slide 17: Intellectual Property
17January 2017 Intellectual Property Technology U.S. Europe Micropump® July 2027 July 2023 LiquiTime® September 2025 April 2023 Trigger Lock™ April 2027 May 2026 (pending) Medusa™ June 2031 June 2027 (pending) Product U.S. Karbinal™ ER March 2029 Flexichamber® March 2028 Product specific IP combined
Slide 18: Non GAAP Financial Results
18January 2017 Non GAAP Financial Results *Reconciliations from GAAP to Non-GAAP can be found in the appendix 2016 2015 Total revenue 107,161 128,441 (21,280) - Cost of products and services sold (3rd Party) 9,132 8,473 659 Intercompany cost of products sold - - - Cost of products and services sold
Slide 19: Cash Flow Summary
19January 2017 Cash Flow Summary (in $000s) 2016 2015 TOTAL Cash and Marketable Securities Beginning Balance 144,802$ 92,834$ Operating Cash Flows (excluding tax and earnout/royalty payments) 49,639 92,277 Tax Payments (22,200) (34,382) Earnout/Royalty Payments (24,229) (17,655) Repayment of Debt -
Slide 20: Investment Highlights
20January 2017 Investment Highlights Phase III Trial Growing Product Portfolio 2017 Outlook − 2016 revenues expected near $143 million − $149.7 million cash & marketable securities at 9/30/16 − Cash flow positive − No bank debt − Phase III trial FT218 − Current market size > $1 billion − Data expect
Slide 21: Appendix
January 2017 21 Appendix
Slide 22: GAAP to Non-GAAP Adjustments, Nine Months 2016
22January 2017 GAAP to Non-GAAP Adjustments Nine Months Ended September 30, 2016: (in thousands - USD$) Include GAAP Intangible asset amortization Foreign exchange (gain)/loss Purchase accounting adjustments - FSC Contingent related party payable fair value remeasurements Contingent related party pa
Slide 23: GAAP to Non-GAAP Adjustments, Nine Months 2015
23January 2017 Nine Months Ended September 30, 2015: (in thousands - USD$) Include GAAP Intangible asset amortization Foreign exchange (gain)/loss Contingent related party payable fair value remeasurements Contingent related party payable paid/accrued Total Adjustments NON-GAAP Product sales and ser
Slide 24: Trigger Lock
24January 2017 Trigger Lock™ • Sustained release Micropump®- based particles that are resistant to crushing • Resistance of drug extraction through alcohol, water and other mediums • Prevention of abuse by injection through use of viscosifying ingredients • Preservation of the drug's bioavailability
Slide 25: Medusa
25January 2017 Medusa™ Release of the unmodified drug by diffusion, disaggregation of the depot and competition with endogenous proteins over several days Depot formation Drug Vitamin EGlutamic acid Day 1Injection Day X* Natural and safe components disappearing progressively *By adjusting polymer co
Slide 26: Product & Safety Information
26January 2017 Product & Safety Information Please click below or visit our websites for full prescribing and safety information for our marketed products Bloxiverz® www.bloxiverz.com Vazculep® www.vazculep.com Akovaz™ www.akovaz.com Karbinal™ ER www.karbinaler.com Aciphex® Sprinkle™ http://www.acip
Avadel Pharmaceuticals — Investor Presentation (January 2017) on 6ix